Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
What is the ticker symbol for Alzamend Neuro, Inc.? What does ALZN stand for in stocks?
ALZN is the stock ticker symbol of Alzamend Neuro, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Alzamend Neuro, Inc. (ALZN)?
As of Fri Dec 20 2024, market cap of Alzamend Neuro, Inc. is 6.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of ALZN stock?
You can check ALZN's fair value in chart for subscribers.
Is Alzamend Neuro, Inc. a good stock to buy?
The fair value guage provides a quick view whether ALZN is over valued or under valued. Whether Alzamend Neuro, Inc. is cheap or expensive depends on the assumptions which impact Alzamend Neuro, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALZN.